Go Deep
Filana Therapeutics, Inc.
Filana Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,069 | -0.8 | 0.56 | 0.00 | 69.46 |
| Oct 2026 | 23,028 | -0.9 | 0.58 | 0.00 | 72.25 |
| Oct 2026 | 23,064 | -0.8 | 0.53 | 0.00 | 66.63 |
| Oct 2026 | 21,295 | -0.8 | 0.52 | 0.00 | 64.66 |
| Oct 2026 | 21,241 | -0.8 | 0.52 | 0.00 | 65.28 |
| Oct 2026 | 21,211 | -0.8 | 0.50 | 0.00 | 62.36 |
| Oct 2026 | 21,217 | -0.8 | 0.50 | 0.00 | 61.74 |
Filana Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -8,603,000.0 | -10,331,000.0 | -12,539,000.0 | -10,807,000.0 |
| EPS | -0.2 | -0.2 | -0.3 | -0.2 |
Filana Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -90,973,000.0 | -24,342,000.0 | -97,217,000.0 | -76,246,000.0 | — |
| EPS | -1.9 | -0.5 | -2.3 | -1.9 | — |
Filana Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 118,355,000.0 | 157,533,000.0 | 151,663,000.0 | 234,834,000.0 | — |
| Total Liabilities | 43,952,000.0 | 11,829,000.0 | 14,195,000.0 | 7,295,000.0 | — |
| Total Equity | 74,403,000.0 | 145,704,000.0 | 137,468,000.0 | 227,539,000.0 | — |
Owes vs Owns
Filana Therapeutics, Inc. owed $0.39 for every $1 it owned in Jun 2026, up from $0.03 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.39× | 0.37× | 0.08× | 0.09× | 0.03× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Filana Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 80.7%Fixed assets (tangible) 17.4%Other assets 1.8%
How it's funded — Dec 2025
Payables 35.2%Other liabilities 1.9%Shareholders' equity 62.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 95.5 | 128.6 | 121.1 | 201.0 |
| Receivables | 0.1 | 0.9 | 1.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 20.6 | 21.0 | 21.9 | 23.0 |
| Intangible assets | 0.0 | 0.0 | 0.2 | 0.6 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 2.1 | 7.0 | 7.5 | 10.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.1 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 41.6 | 7.7 | 10.6 | 4.0 |
| Other liabilities | 2.3 | 4.2 | 3.6 | 3.1 |
| Shareholders' equity | 74.4 | 145.7 | 137.5 | 227.5 |
| Net tangible assets | 74.4 | 145.7 | 137.3 | 226.9 |
Filana Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -32,252,000.0 | -116,929,000.0 | -82,025,000.0 | -77,514,000.0 | — |
| Investing Activities | -581,000.0 | -103,000.0 | -414,000.0 | -2,712,000.0 | — |
| Financing Activities | -239,000.0 | 124,470,000.0 | 2,560,000.0 | 47,804,000.0 | — |